NASDAQ:XNCR - Xencor Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.11
  • Forecasted Upside: -11.11 %
  • Number of Analysts: 9
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$48.50
▲ +0.39 (0.81%)
1 month | 3 months | 12 months
Get New Xencor Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XNCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XNCR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$43.11
▼ -11.11% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Xencor in the last 3 months. The average price target is $43.11, with a high forecast of $56.00 and a low forecast of $21.00. The average price target represents a -11.11% upside from the last price of $48.50.
Buy
The current consensus among 9 investment analysts is to buy stock in Xencor. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
8/2/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/31/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/29/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 2 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 3 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 2 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 2 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 2 sell ratings
1/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2020Cantor FitzgeraldBoost Price TargetOverweight$40.00 ➝ $56.00Low
i
Rating by A. Young at Cantor Fitzgerald
11/6/2020SVB LeerinkBoost Price TargetOutperform$42.00 ➝ $46.00High
i
9/8/2020SVB LeerinkLower Price TargetOutperform$42.00 ➝ $39.00High
i
8/5/2020SVB LeerinkLower Price TargetOutperform$44.00 ➝ $42.00Low
i
8/5/2020MizuhoReiterated RatingBuyLow
i
Rating by Mara Goldstein at Mizuho
7/21/2020MizuhoReiterated RatingBuy$52.00Low
i
Rating by Mara Goldstein at Mizuho
7/8/2020Piper SandlerReiterated RatingBuy$46.00Medium
i
Rating by Edward Tenthoff at Piper Sandler
7/8/2020MizuhoReiterated RatingBuy$52.00Medium
i
Rating by Mara Goldstein at Mizuho
5/13/2020Canaccord GenuityReiterated RatingBuy$52.00Medium
i
5/10/2020NomuraReiterated RatingSell$21.00High
i
5/7/2020MizuhoReiterated RatingBuy$52.00High
i
Rating by Mara Goldstein at Mizuho
3/4/2020BarclaysInitiated CoverageUnderweight$28.00High
i
2/25/2020GuggenheimUpgradeNeutral ➝ Buy$43.00High
i
Rating by Etzer Darout at Guggenheim
2/17/2020MizuhoReiterated RatingBuy$52.00Medium
i
Rating by Mara Goldstein at Mizuho
1/30/2020Royal Bank of CanadaInitiated CoverageOutperform$44.00High
i
12/18/2019MizuhoReiterated RatingBuy$52.00Medium
i
11/20/2019GuggenheimInitiated CoverageHoldHigh
i
Rating by Etzer Darout at Guggenheim
11/6/2019SVB LeerinkLower Price TargetOutperform$52.00 ➝ $44.00Medium
i
Rating by Jonathan Chang at SVB Leerink LLC
11/5/2019MizuhoReiterated RatingBuyMedium
i
Rating by Mara Goldstein at Mizuho
8/8/2019Nomura SecuritiesReiterated RatingSell$21.00Low
i
8/8/2019Canaccord GenuityBoost Price TargetBuy$45.00 ➝ $52.00High
i
8/7/2019SVB LeerinkSet Price TargetBuy$52.00Low
i
Rating by Jonathan Chang at SVB Leerink LLC
8/7/2019Raymond JamesReiterated RatingOutperform ➝ Market PerformHigh
i
8/7/2019WedbushBoost Price TargetOutperform$43.00 ➝ $54.00High
i
8/7/2019GuggenheimDowngradeBuy ➝ NeutralHigh
i
7/8/2019Piper Jaffray CompaniesBoost Price TargetOverweight$56.00 ➝ $67.00Low
i
7/1/2019MizuhoReiterated RatingBuy$52.00High
i
Rating by Mara Goldstein at Mizuho
6/12/2019MizuhoInitiated CoverageBuy ➝ Buy$52.00Medium
i
5/12/2019Cantor FitzgeraldReiterated RatingBuy$40.00High
i
Rating by A. Young at Cantor Fitzgerald
4/12/2019GuggenheimInitiated CoverageBuy$42.00Low
i
4/2/2019Cantor FitzgeraldReiterated RatingBuy$40.00Low
i
Rating by A. Young at Cantor Fitzgerald
3/27/2019Berenberg BankInitiated CoverageBuy ➝ Buy$45.00Low
i
3/14/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$27.85High
i
2/26/2019Piper Jaffray CompaniesBoost Price TargetOverweight$56.00Medium
i
2/22/2019Nomura SecuritiesDowngradeNeutral ➝ Reduce$28.00 ➝ $21.00High
i
2/5/2019Cantor FitzgeraldReiterated RatingBuy$40.00High
i
Rating by A. Young at Cantor Fitzgerald
12/7/2018WedbushBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $44.00Medium
i
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by A. Young at Cantor Fitzgerald
11/6/2018Cantor FitzgeraldReiterated RatingBuy$40.00High
i
10/8/2018WedbushReiterated RatingOutperform$42.00Low
i
9/10/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$56.00High
i
8/8/2018Canaccord GenuityBoost Price TargetBuy$38.00 ➝ $45.00Medium
i
8/7/2018Piper Jaffray CompaniesReiterated RatingTop Pick ➝ OverweightHigh
i
6/7/2018BTIG ResearchInitiated CoverageBuy$56.00Low
i
5/9/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$36.00 ➝ $38.00Medium
i
4/5/2018Nomura SecuritiesLower Price TargetNeutral$28.00Low
i
3/29/2018Cantor FitzgeraldReiterated RatingBuy$37.00Low
i
Rating by W. Tanner at Cantor Fitzgerald
3/28/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$36.00Low
i
Rating by J. Chang at SVB Leerink LLC
3/19/2018WedbushBoost Price TargetOutperform$38.00 ➝ $39.00Low
i
3/1/2018Cantor FitzgeraldReiterated RatingOverweight$37.00High
i
Rating by W. Tanner at Cantor Fitzgerald
2/22/2018Cantor FitzgeraldInitiated CoverageBuy$33.00Low
i
Rating by W. Tanner at Cantor Fitzgerald
11/29/2017Cantor FitzgeraldInitiated CoverageOverweight$33.00Medium
i
Rating by W. Tanner at Cantor Fitzgerald
11/12/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00N/A
i
10/23/2017Canaccord GenuitySet Price TargetBuy$36.00N/A
i
Rating by Arlinda Lee at Canaccord Genuity
8/8/2017Canaccord GenuityReiterated RatingBuy$36.00High
i
6/16/2017WedbushReiterated RatingOutperform$29.00Low
i
6/6/2017WedbushReiterated RatingOutperform$29.00High
i
5/10/2017WedbushReiterated RatingOutperform$29.00High
i
3/2/2017WedbushReiterated RatingOutperform ➝ Outperform$27.00 ➝ $33.00N/A
i
3/1/2017Nomura InstinetInitiated CoverageNeutral ➝ Neutral$21.00N/A
i
3/1/2017Nomura SecuritiesInitiated CoverageNeutralN/A
i
11/28/2016Canaccord GenuitySet Price TargetBuy$32.00N/A
i
Rating by Arlinda Lee at Canaccord Genuity
11/14/2016Canaccord GenuitySet Price TargetBuy$27.00N/A
i
Rating by Arlinda Lee at Canaccord Genuity
11/3/2016SVB LeerinkReiterated RatingBuy$26.00N/A
i
10/4/2016Piper Jaffray CompaniesInitiated CoverageOverweight$35.00N/A
i
9/12/2016Canaccord GenuitySet Price TargetBuy$27.00N/A
i
Rating by arlinda lee at Canaccord Genuity
9/12/2016WedbushReiterated RatingOutperform$27.00N/A
i
6/29/2016SVB LeerinkReiterated RatingOutperform$18.00N/A
i
6/28/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Arlinda Lee at Canaccord Genuity
6/28/2016WedbushReiterated RatingOutperform$27.00N/A
i
5/3/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Arlinda Lee at Canaccord Genuity
5/2/2016OppenheimerReiterated RatingBuyN/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
4/4/2016Canaccord GenuityReiterated RatingBuy$20.00N/A
i
Rating by Arlinda Lee at Canaccord Genuity
3/9/2016OppenheimerReiterated RatingOutperform$28.00N/A
i
3/8/2016SVB LeerinkLower Price TargetOutperform$22.00 ➝ $18.00N/A
i
3/8/2016Canaccord GenuityReiterated RatingBuy$20.00N/A
i
Rating by Arlinda Lee at Canaccord Genuity
(Data available from 1/24/2016 forward)
Xencor logo
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; Amgen Inc.; Catalent Pharma Solutions LLC.; Janssen Biotech, Inc.; MorphoSys AG; and Incyte Corporation. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Read More

Today's Range

Now: $48.50
$46.06
$48.79

50 Day Range

MA: $45.53
$38.85
$49.90

52 Week Range

Now: $48.50
$19.35
$50.56

Volume

201,688 shs

Average Volume

251,292 shs

Market Capitalization

$2.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Xencor?

The following sell-side analysts have issued reports on Xencor in the last year: Barclays PLC, Canaccord Genuity, Cantor Fitzgerald, Guggenheim, Mizuho, Nomura, Piper Sandler, Royal Bank of Canada, SVB Leerink LLC, TheStreet, and Zacks Investment Research.

What is the current price target for Xencor?

9 Wall Street analysts have set twelve-month price targets for Xencor in the last year. Their average twelve-month price target is $43.11, suggesting a possible downside of 11.1%. Cantor Fitzgerald has the highest price target set, predicting XNCR will reach $56.00 in the next twelve months. Nomura has the lowest price target set, forecasting a price of $21.00 for Xencor in the next year.

What is the current consensus analyst rating for Xencor?

Xencor currently has 2 sell ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XNCR will outperform the market and that investors should add to their positions of Xencor.

What other companies compete with Xencor?

How do I contact Xencor's investor relations team?

Xencor's physical mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company's listed phone number is 626-305-5900 and its investor relations email address is [email protected] The official website for Xencor is www.xencor.com.